COMMUNIQUÉS West-GlobeNewswire

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
02/03/2026
PYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia NewBridge Pharmaceuticals, a regional specialty company, will continue to [...]
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
02/03/2026
ROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today [...]
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
02/03/2026
RAMSEY, N.J. and BOCA RATON, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to [...]
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
02/03/2026
Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway: - APEX Phase 2 Part A 52-week data expected this month - APEX Phase 2 Part B 16-week data [...]
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
02/03/2026
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company’s board of directors as of March 1. Most recently [...]
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
02/03/2026
RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours, and [...]
Egle Therapeutics and Consortium Partners Awarded €8 Million Grant from Horizon Europe to Advance Clinical Development of EGL-001 in Neoadjuvant Head and Neck Cancer
02/03/2026
PARIS, March 02, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in [...]
Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland
02/03/2026
Bagsværd, Denmark, 2 March 2026 – Novo Nordisk today announced an investment of 432 million euro (approx. DKK 3.2 billion) in its facility in Monksland, Athlone, Ireland. This tabletting facility will provide [...]
Notification of managers’ transactions
02/03/2026
ANNOUNCEMENT NO. 302 2 March 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in [...]
VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.
02/03/2026
ZURICH, SWITZERLAND – March 2, 2026 -- VERAXA Biotech AG (“ VERAXA ”), an emerging leader in designing novel cancer therapies, today announced that its shareholders approved the merger between VERAXA and Veraxa Biotech [...]
Paul Chaplin Steps Down as CEO of Bavarian Nordic
02/03/2026
COPENHAGEN, Denmark, March 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today, that the Board of Directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons. Paul [...]
Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
02/03/2026
Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD Third global orphan drug designation for [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)
02/03/2026
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with FENhance 2 results showing [...]
Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4
02/03/2026
Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4 La désignation s’appuie sur les données positives d’une étude de phase 2 sur le rilzabrutinib dans la [...]
InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
02/03/2026
BEIJING, March 01, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next generation TRK inhibitor [...]
Investor Education Webinar
01/03/2026
The Future of Prostate Imaging: What do physicians want? MELBOURNE, Australia and INDIANAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) invites investors to join [...]
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
01/03/2026
-- - 18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -- March 20, 2026 [...]
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
01/03/2026
– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of - 1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong [...]
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
01/03/2026
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an [...]

Pages